Absci Corporation (ABSI) vs Zenas BioPharma, Inc. (ZBIO)

Absci Corporation and Zenas BioPharma, Inc. are both Biotechnology companies. Absci Corporation and Zenas BioPharma, Inc. are of similar size ($1.8B and $1.8B). Zenas BioPharma, Inc. has the higher net margin (0.00% vs −7,756.4%) and the higher return on invested capital (0.00% vs −174.7%). Across the 13 metrics below, Absci Corporation leads on 7 and Zenas BioPharma, Inc. on 6.

Valuation

Metric ABSI ZBIO Biotechnology median
P/E n/m n/m 7.88
P/S 982.56 n/m 11.47
P/B 6.23 6.95 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 853.84 n/m 10.73
Earnings yield (8.21%) (33.02%) (28.84%)
Free cash flow yield (7.09%) (13.15%) (23.03%)

Profitability

Metric ABSI ZBIO Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (8,084.50%) 0.00% 0.00%
Net margin (7,756.37%) 0.00% 0.00%
Free cash flow margin (6,969.83%) 0.00% 0.00%
Return on equity (57.72%) (199.04%) (57.72%)
Return on assets (50.57%) (97.39%) (49.22%)
Return on invested capital (174.74%) 0.00% 0.00%

Growth

Metric ABSI ZBIO Biotechnology median
Revenue growth (TTM) (62.28%) — 5.64%
EPS growth (last fiscal year) 10.64% 29.04% —
Revenue growth, 5-year CAGR (10.14%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ABSI ZBIO Biotechnology median
Debt to equity 0.00 1.57 0.00
Current ratio 10.63 9.93 4.73
Net debt to EBITDA 1.32 0.69 0.96

Dividend

Metric ABSI ZBIO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ABSI ZBIO Biotechnology median
Market cap 1.81b 1.79b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack